Session Details
[27-53-pm1]Clinical Pharmacy 2, Development of novel medicines and formulations/Ordering/Formulation testing/Drug information
Fri. Mar 27, 2026 1:10 PM - 3:10 PM JST
Fri. Mar 27, 2026 4:10 AM - 6:10 AM UTC
Fri. Mar 27, 2026 4:10 AM - 6:10 AM UTC
Room 53 (B306, Bldg. 1, Area 2 [3F])
Discusser: Kazuaki Taguchi, Masaki Kobayashi
[27-53-pm1-01S]Enhancement effects of solvents and nonionic surfactants on skin permeation of olanzapine
○YUMERI MIURA1, YURI IKEUCHI1, MAIKO NISHIOKA1, YUSUKE KINOSHITA1, IKKI SHIBAZAKI1, TETSUYA FUKUDA2, YASUKO OBATA1 (1. Hoshi Univ., 2. JIHS)
[27-53-pm1-02S]Elucidation of enhancement mechanism of olanzapine skin permeation enhancers by FTIR analysis
○Maiko Nishioka1, YURI IKEUCHI1, YUMERI MIURA1, YUSUKE KINOSHITA1, IKKI SHIBAZAKI1, TETSUYA FUKUDA2, YASUKO OBATA1 (1. Hoshi Univ., 2. JIHS)
[27-53-pm1-03S]Evaluation of Identifiability of Canalia® Combination OD Tablets in Unit-dose Packaging Inspection Machines
○Masato Saraumi1, Yuka Shono1, Yusuke Fujii2, Yoshihiro Kawamoto2, Hiroshi Matoba2, Tomomi Fukuyoshi2, Hidenori Sagara1 (1. Fac.Pharm.Sci., 2. Lady Drug Store.Co.,Ltd.)
[27-53-pm1-04S]A Study on Differences in User Experience of Transdermal Tape Formulations: Comparison of Brand-Name and Generic Tulobuterol Tapes via Physicochemical Property Evaluation
○Hina Tabayashi1, Motoki Inoue1, Atsushi Ishimura1 (1. Hoshi Univ.)
[27-53-pm1-05S]A Comparative Study on the Efficacy of Donepezil and Galantamine for Cognitive Symptoms and Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease
○Momoko Tanigawa1, Anna Kiyomi1, Kensuke Yoshida1, Munetoshi Sugiura1 (1. Tokyo University of Pharmacy and Life Sciences)
[27-53-pm1-06S]Predictivity of the nonclinical toxicity studies on adverse events in the clinical trials of the new drugs for the cardiovascular diseases
○Erika Ishida1, Ami Mizuta1, Masaki Takaishi1, Akio Kobayashi1 (1. Pharm.Sci.,IUHW.)
[27-53-pm1-07S]Development of a machine learning-based predictive model for identifying medications associated with angioedema
○Kasumi Meguro1, Mizuho Asada1, Yoshihiro Uesawa1 (1. Meiji Pharm.Univ.)
[27-53-pm1-08S]A Comprehensive Analysis of the Risk of Anticancer Drug–Induced Autoimmune Diseases Using the FAERS Database
○Yuina Kawara1, Mizuho Asada1, Yoshihiro Uesawa1 (1. Meiji Pharm.Univ.)
[27-53-pm1-09S]Analysis of Cardiotoxicity Associated with Anticancer Agents Using
○Keisuke Ishida1, Shinsuke Miyazawa1, Mizuho Asada1, Yoshihiro Uesawa1 (1. Meiji Pharm Univ)
[27-53-pm1-10]Development of a Machine Learning Model for Predicting Novel Adverse Reactions in Antidiabetic Drugs from 2022 to 2025 Using ADR Profile Similarity
○Sorama Aoki1, Mane Ikeda1, Junko Kawakami1 (1. Fac. Pharm., Tohoku Med. Pharm. Univ.)
